Farge D, Charpentier B, Simonneau G, Benoit G, Fries D
Nephrologie. 1985;6(2):53-7.
Rifampicin is considered as one of the most potent antituberculous agents and is often used in renal transplant recipients. However, acute cellular rejection episodes were observed when rifampicin was prescribed in 4 tolerant renal transplant recipients. Acute rejection occurred in 3 out of the 5 patients, despite doubled daily dose of steroids. First, rifampicin is an enzymatic inducer and accelerates steroid metabolism. Secondly, rifampicin per se is an immunosuppressive drug, as already proved in animals. Rifampicin interferes with the active mechanisms involved in specific transplantation tolerance. In conclusion, we recommend a very cautious use of rifampicin in kidney transplant recipients.
利福平被认为是最有效的抗结核药物之一，常用于肾移植受者。然而，在4名耐受的肾移植受者中使用利福平时，观察到急性细胞排斥反应。尽管每日类固醇剂量加倍，但5名患者中有3名发生了急性排斥反应。首先，利福平是一种酶诱导剂，会加速类固醇代谢。其次，利福平本身就是一种免疫抑制药物，这已在动物实验中得到证实。利福平会干扰参与特异性移植耐受的活性机制。总之，我们建议在肾移植受者中非常谨慎地使用利福平。
